Investment Analysts’ Weekly Ratings Updates for Arrowhead Pharmaceuticals (ARWR)

Several brokerages have updated their recommendations and price targets on shares of Arrowhead Pharmaceuticals (NASDAQ: ARWR) in the last few weeks:

  • 7/5/2024 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock, down previously from $90.00.
  • 7/2/2024 – Arrowhead Pharmaceuticals was upgraded by analysts at StockNews.com to a “sell” rating.
  • 6/26/2024 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
  • 6/20/2024 – Arrowhead Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
  • 6/11/2024 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
  • 6/5/2024 – Arrowhead Pharmaceuticals is now covered by analysts at The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $31.00 price target on the stock.
  • 6/3/2024 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
  • 6/3/2024 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
  • 5/13/2024 – Arrowhead Pharmaceuticals had its price target lowered by analysts at Morgan Stanley from $36.00 to $27.00. They now have an “equal weight” rating on the stock.
  • 5/13/2024 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
  • 5/10/2024 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.

Arrowhead Pharmaceuticals Price Performance

ARWR stock traded up $0.15 during midday trading on Monday, hitting $25.72. The stock had a trading volume of 167,187 shares, compared to its average volume of 1,310,940. The firm has a market cap of $3.19 billion, a price-to-earnings ratio of -6.05 and a beta of 0.94. The business has a 50-day moving average of $24.66 and a two-hundred day moving average of $28.26. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $20.67 and a 52-week high of $39.83.

Arrowhead Pharmaceuticals (NASDAQ:ARWRGet Free Report) last released its earnings results on Thursday, May 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.96). Arrowhead Pharmaceuticals had a negative return on equity of 140.72% and a negative net margin of 163.32%. During the same quarter in the previous year, the company earned $0.45 earnings per share. The business’s quarterly revenue was down 100.0% compared to the same quarter last year. Research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -3.05 earnings per share for the current year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, Director Victoria Vakiener sold 1,799 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $23.31, for a total value of $41,934.69. Following the sale, the director now directly owns 30,205 shares of the company’s stock, valued at approximately $704,078.55. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, insider Tracie Oliver sold 9,394 shares of the company’s stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $25.28, for a total value of $237,480.32. Following the transaction, the insider now owns 127,107 shares in the company, valued at approximately $3,213,264.96. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Victoria Vakiener sold 1,799 shares of the firm’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $23.31, for a total transaction of $41,934.69. Following the sale, the director now owns 30,205 shares of the company’s stock, valued at $704,078.55. The disclosure for this sale can be found here. Insiders own 4.50% of the company’s stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the company. Washington Trust Advisors Inc. bought a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at approximately $25,000. Neo Ivy Capital Management bought a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at $41,000. Quest Partners LLC purchased a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at $45,000. Friedenthal Financial bought a new stake in Arrowhead Pharmaceuticals in the 4th quarter worth about $51,000. Finally, Van ECK Associates Corp raised its position in Arrowhead Pharmaceuticals by 22.9% in the 4th quarter. Van ECK Associates Corp now owns 2,395 shares of the biotechnology company’s stock worth $73,000 after buying an additional 447 shares during the last quarter. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

Read More

Receive News & Ratings for Arrowhead Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.